Cynapsus is a central nervous system pharmaceutical company that develops sublingual film product to treat the motor symptoms of Parkinson's disease.
Business Model:
Revenue: $13.3M
Employees: 11-50
Cynapsus was acquired by
Sunovion Pharmaceuticals.
The acquisition happend on 2016-08-31.
Details of the transaction were not public
Address: 828 Richmond Street West
City: Toronto
State: ontario
Zip: M6J 1C9
Country: CA
Cynapsus is a central nervous system pharmaceutical company that develops sublingual film product to treat the motor symptoms of Parkinson's disease.
Contact Phone:
+14167032449
Contact Email:
Listed Exchange:
TMX Group - Toronto Stock Exchange
IPO Date:
6/17/2015
Ticker Symbol:
CTH
Amount Raised:
$72M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2013 | Equity | $3.9M | 3/2015 | Equity | $16.8M |
OrbiMed Aisling Capital Venrock Broadfin Capital Sphera Funds Management Pura Vida Investments Dafna Capital Management Dexcel Pharma Technologies Ltd |
4/2014 | Venture Round | $14.5M | 3/2015 | Venture Round | 3 | $16.6M |
Aisling Capital OrbiMed Venrock Aisling Capital OrbiMed Venrock |
2/2013 | Equity | $4.1M | 6/2015 | IPO | $72.5M | 7/2014 | Grant | $500k | 3/2013 | Venture Round | $4.1M | 3/2012 | Venture Round | $939.5k |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|